News for Soleno Therapeutics, Inc. (SLNO)

On May 29, 2025, Carlyle Group Inc. (Trades, Portfolio) executed a significant transaction involving StandardAero Inc. The firm reduced its holdings in Standard

Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) has achieved a major regulatory milestone as the European Medicines Agency (EMA) validated its Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets (formerly DCCR) to treat hyperphagia in Prader-Willi syndrome (PWS) for patients aged four and older. This follows the recent U.S. FDA approval of the drug, now marketed as VYKAT […]

Summary Soleno Therapeutics Inc (SLNO), a biopharmaceutical company focused on developing treatments for rare diseases, announced on May 21, 2025, that it will

REDWOOD CITY, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (”œSoleno”) ( SLNO), a biopharmaceutical company developing novel therapeu

**media[632940]**

Summary Soleno Therapeutics Inc (SLNO), a biopharmaceutical company focused on developing treatments for rare diseases, announced its participation in the Pedia

REDWOOD CITY, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) ( SLNO), a biopharmaceutical company developing novel therapeutics f

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look at where Soleno Therapeutics, Inc. (NASDAQ:SLNO) stands against other best performing healthcare stocks to buy now. Trump’s Healthcare Executive Order Brings a Win On April 15, CNBC reported that President Trump’s […]

REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) ( SLNO), a biopharmaceutical company developing novel therapeutics f

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ETCompany ParticipantsBrian Ritchie - LifeSci AdvisorsAnish...

**media[618063]**

Piper Sandler has revised its price target for Soleno Therapeutics (SLNO), elevating it from $93 to $145, while maintaining an Overweight rating on the stock. T

**media[602790]**

Soleno Therapeutics (SLNO) launches VYKATâ„¢ XR, the FDA-approved treatment for hyperphagia in Prader-Willi syndrome (PWS). VYKAT XR is the first and on

Summary Soleno Therapeutics Inc (SLNO), a biopharmaceutical company focused on developing treatments for rare diseases, announced on April 14, 2025, the U.S. co

First prescriptions delivered to individuals with PWS REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) ( SLNO), a

**media[594183]**

We recently published a list of 10 Stocks Outperform Broader Market Last Week. In this article, we are going to take a look at where Soleno Therapeutics Inc.